Under normal circumstances, the human body contains a small amount of lactic acid in the blood, which is mainly produced by glucose or glycogenolysis in tissues such as muscles, skin, brain and cells. After lactic acid is produced, it can be converted into glycogen or pyruvate, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. The final metabolite of sodium lactate is sodium bicarbonate, which can be used to correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from the blood and extracellular fluid. The main organs for lactic acid degradation are the liver and kidneys. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor; in addition, the effect of sodium lactate is not as rapid as sodium bicarbonate.

It can be used to correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from the blood and extracellular fluid. The main organs for lactic acid degradation are the liver and kidneys. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor; in addition, the effect of sodium lactate is not as rapid as that of sodium bicarbonate.

This product is an antifibrinolytic drug that can qualitatively inhibit the binding of plasminogen to fibrin, prevent its activation, and thus inhibit fibrinolysis; high concentrations (100 mg/L) directly inhibit the activity of plasmin and achieve a hemostatic effect.

This product is a highly selective 5HT3 receptor antagonist, which has a good preventive and therapeutic effect on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. It inhibits the occurrence of nausea and vomiting by antagonizing the 5HT3 receptors in the central chemoreceptor area and peripheral vagus nerve endings, without side effects such as extrapyramidal reactions and excessive sedation.

Fusultiamine is a new derivative of vitamin B1. It is rapidly converted into active thiamine in the body and is not decomposed by thiaminase in the body. It has strong affinity for tissues, high concentrations in organs and blood, and can be maintained for a long time. It has the characteristics of high efficiency, long-term effect, and low toxicity. Like vitamin B1, active thiamine combines with pyrophosphate in the body to form a coenzyme, which participates in the oxidative decarboxylation reaction of pyruvate and a-ketoglutaric acid in sugar metabolism and is necessary for sugar metabolism. When it is deficient, oxidation is blocked to form pyruvate, lactic acid accumulates, and affects the body's energy supply. Its symptoms are mainly manifested in the nervous and cardiovascular systems, with multiple peripheral neuritis affecting both sensory nerves and motor nerves, manifested as paresthesia, neuralgia, limb weakness, and muscle soreness and atrophy.